- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05087342
Latino Semaglutide Study (LSS)
A Randomized Latino Semaglutide 2.4mg Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Warren Peters, MD
- Phone Number: (909) 558-0182
- Email: wpeters@llu.edu
Study Contact Backup
- Name: Amandeep Kaur, MPH
- Phone Number: (909) 558-0182
- Email: akaur1@llu.edu
Study Locations
-
-
California
-
Loma Linda, California, United States, 92350
- Recruiting
- Loma Linda University Health
-
Contact:
- Warren Peters, MD
- Phone Number: 909-558-0182
- Email: wpeters@Llu.edu
-
Contact:
- Amandeep Kaur, BS
- Phone Number: 909-558-0182
- Email: akaur1@llu.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Self-identify as being of Hispanic/Latino ethnicity
- BMI >30
- Age 18-75 years old
- Able to provide informed consent before any trial related activities
Exclusion Criteria:
- Current cancer treatment
- Diabetes, Type 1 or Type 2
- Eating disorders
- Medication use targeting the GPL-1 system
- In the last 30 days, attempted to lose weight by lifestyle modification alone or with the use of anti-obesity medications resulting in more than 5 pounds of weight loss.
- History of bariatric surgery
- Use of obesogenic medications (including but not limited to steroids, haloperidol, clozapine, risperidone, olanzapine, amitriptyline, imipramine, paroxetine, and lithium) which cannot be substituted or stopped.
- Pregnant or planning to become pregnant in the next 8 months
- Genetic disorders and/or physical or mental handicaps that would limit participation in the study and/or the intensive lifestyle intervention.
- Any contraindication to semaglutide 2.4 mg including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2, hypersensitivity to semaglutide 2.4 mg or any product components.
- Any known or suspected allergy to semaglutide 2.4 mg or related products
- Previous participation in this trial, either initial screening or group randomization
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intervention Group
Will receive active medication semaglutide subcutaneously, once weekly, self-injection. Month 1 - 0.24 mg SC once weekly x 4 weeks.(IE-1) Month 2- 0.5 mg SC once weekly x 4 weeks.(IE-2) Month 3 -1 mg SC once weekly x 4 weeks.(IE-3) Month 4 - 1.7 mg SC once weekly x 4 weeks.(IE-4) Month 5 - 2.4 mg SC once weekly x 4 weeks. (IE-5) Month 6 - 2.4 mg SC continue once weekly x 8 weeks.(IE-6) Month 7 - completion visit (IE-7) |
The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.
|
Placebo Comparator: Control Group
Will receive placebo, subcutaneously, once weekly, self-injection throughout study duration.
|
A placebo will be given to the control group per the schedule outlined in the armed description.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of weight loss.
Time Frame: Change between baseline and final study visit, seven months post baseline.
|
Assessment will be based on pounds lost between baseline and final study visit.
|
Change between baseline and final study visit, seven months post baseline.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Food Addiction Assessment
Time Frame: Change between baseline and month four of treatment.
|
Yale Food Addiction Scale Survey administered to subjects at baseline and month four of treatment.
Assessment results based on multiple survey questions regarding intake of specific food types (sugar, starch, sweet, salty, savory).
|
Change between baseline and month four of treatment.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Warren Peters, MD, Loma Linda University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5210364
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
-
Consorcio Centro de Investigación Biomédica en...Maimónides Biomedical Research Institute of Córdoba; Instituto de Salud Carlos... and other collaboratorsActive, not recruiting
-
University of HoustonBaylor College of MedicineCompleted
Clinical Trials on Semaglutide 2.4mg
-
Vanderbilt University Medical CenterNational Institute of Allergy and Infectious Diseases (NIAID)Recruiting
-
Bio-Thera SolutionsUnknown
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
Novo Nordisk A/SCompletedType 2 Diabetes | Healthy VolunteersUnited States, Canada
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, Italy, Spain, Canada, Hungary
-
Novo Nordisk A/SCompletedObesity | OverweightJapan, Korea, Republic of
-
Novo Nordisk A/SCompletedOverweight or Obesity | Metabolism and Nutrition DisorderUnited States, India, Mexico, Russian Federation, United Kingdom, Canada, Denmark, Finland, Belgium, Japan, Taiwan, France, Poland, Germany, Bulgaria, Argentina, Puerto Rico
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, India, Japan, Russian Federation, United Kingdom, Canada, Spain, South Africa, Germany, Greece, United Arab Emirates, Argentina, Puerto Rico
-
Novo Nordisk A/SCompletedObesityUnited States, Israel, United Kingdom, Denmark, Germany, Netherlands, Canada, Argentina, Czechia, Hungary, Poland, Spain, Australia
-
Novo Nordisk A/SCompletedObesity | Diabetes Mellitus, Type 2 | OverweightKorea, Republic of, Hong Kong, Brazil, China